Karyopharm to Present Data on Its Novel Oral PAK4

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Karyopharm to Present Data on Its Novel Oral PAK4 Allosteric Modulator (PAM) at the American Association for Cancer Research Annual Meeting

NEWTON, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI ), a clinical-stage pharmaceutical company, today announced that five abstracts describing the company's PAK4 allosteric modulators (PAMs) have been selected for presentation at the 2015 Annual Meeting of the American Association for Cancer Research (AACR) taking place April 18-22 in Philadelphia. These preclinical abstracts, which represent both company and investigator-sponsored research, present data related to intercellular PAMs effects on K-Ras and WNT/ß-catenin signaling pathways and the characterization of single agent antitumor activity. Detailed results from these studies will be presented at the conference.

"We are pleased to be presenting updated research on Karyopharm's PAK4 allosteric inhibitors at the AACR annual meeting," said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. "Presentations on our PAK4 inhibitors include effects on key signaling pathways along with activity in several solid tumor models, supporting further development of these novel oral PAMs."

Abstracts related to Karyopharm's novel, selective, oral small-molecule PAMs include:

-  Oral Presentation : Overcoming drug resistance and stemness in oncogenic K-Ras driven pancreatic ductal adenocarcinoma through PAK4 inhibition 
Author:  Azmi, Wayne State University 
Presentation:  4688
Session:  MS.ET06.01. Exploiting the MAPK Pathway in Cancer 
Date/Time:  Tuesday, April 21, 3:20 - 3:35 PM 
   
-  Poster Title : Novel PAK4 allosteric modulators (PAMs) provide potential therapeutic options in human gastric cancer
Author:  Chien, Cancer science institute of Singapore
Poster:  138/21
Session:  PO.MCB04.02. Kinases and Inhibitors
Date/Time:  Sunday, April 19, 1:00 - 5:00 PM
   
-  Poster Title : Inhibition of PAK4 attenuates renal cell carcinoma (RCC) growth
Author:  Abu Aboud, UC Davis
Poster:  2644/15 
Session:  PO.ET07.02. Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy
Date/Time:  Monday, April 20, 1:00 - 5:00 PM
   
-  Poster Title : Inhibition of PAK4 blocks growth of breast cancer cells 
Author:  Rane, Rutgers University 
Poster:  4039/24
Session:  PO.MCB01.06. Tumor Cell-Stromal and Cell-Cell Interactions 
Date/Time:  Tuesday, April 21, 1:00 - 5:00 PM 
   
-  Poster Title : PAK4 allosteric modulators (PAMs) repress the Wnt/ß-catenin signaling pathway and tumor growth 
Author:  Senapedis, Karyopharm 
Poster:  5404/16 
Session:  PO.ET06.07. Kinase Inhibitors and Other Targets 
Date/Time:  Wednesday, April 22, 8:00 AM - 12:00 PM 

About PAK4

P21-Activated Kinase 4 (PAK4) is a member of the PAK family of proteins that regulate cell survival, cell division and apoptosis. PAK4 is a key downstream effector of the K-Ras pathway and mediates cell motility, proliferation, and survival. Karyopharm has identified selective, novel, orally-bioavailable small molecule PAK4 allosteric modulators (PAMs) with demonstrated anti-tumor activity both in vitro and in vivo. Karyopharm's lead PAMs have shown promising results in many preclinical models for the treatment of a wide variety of cancers.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI ) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). SINE™ compounds have also shown biological activity in models of cancer, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit  www.karyopharm.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, including the timing of initiation of certain trials and of the reporting of data from such trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any of Karyopharm's SINE™ compounds, including Selinexor (KPT-330) or any PAK4 inhibitor, or any other drug candidate that Karyopharm is developing will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission (SEC) as of March 13, 2015. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Justin Renz (617) 658-0574 Gina Nugent (617) 460-3579

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 104

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 81

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 79

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading

Top 5 Most Recently Viewed Articles

Larry Chen's Transformative Journey in Automotive Photography

Updated Category News Views 460

Celebrating 20 Years of Automotive Photography Renowned automotive photographer Larry Chen presents his first-ever book titled Life at Shutter Speed: Two Decades of Larry Chen Photography. This extensive 400-page work features exceptional highlights from Chen's impressive career, along with captivating never-before-seen images. What’s Inside the Book? Life at Shutter...

Continue Reading
Kemper Corporation Achieves Record Stock High of $71.71

Updated Category News Views 157

Kemper Corporation Achieves New Stock Milestone Kemper Corporation (NYSE: KMPR) has reached an impressive milestone by achieving a remarkable 52-week high of $71.71. This achievement not only signifies a substantial uptrend for the diversified insurance holding but also reflects a commendable 67.95% increase in its stock value over the past year. The rising confidence...

Continue Reading
Rising Online Vaping Markets: A Challenge for Local Stores

Updated Category News Views 114

Challenges Faced by Local Convenience Stores in Quebec Local convenience stores in Quebec are confronting significant challenges due to the rise of online vaping sales. As these businesses grapple with a ban on flavored vapor products, introduced by Health Minister Christian Dubé, they are witnessing a shift in consumer behavior. This change has driven many customers to...

Continue Reading
Krispy Kreme Shareholders Invited to Join Class Action Lawsuit

Updated Category News Views 485

Krispy Kreme Investors: The Class Action Lawsuit Explained Krispy Kreme, Inc. (NASDAQ: DNUT) is facing a class action lawsuit that is generating significant attention among investors. This suit has been initiated by Robbins LLP following concerns about misleading statements made by the company's executives regarding its partnership with McDonald's. For anyone invested in...

Continue Reading
DexCom, Inc. Class Action Notice: Your Chance to Join Efforts

Updated Category News Views 62

Important Warning for DexCom, Inc. Shareholders Investors holding shares of DexCom, Inc. (NASDAQ: DXCM) should be aware of a critical opportunity to engage in a class action lawsuit. This notice emphasizes the essential details for shareholders who purchased shares during the specified class period. Your Participation Matters Shareholders are urged to reach out promptly...

Continue Reading